Monoclonal Antibody to Annexin A1 (ANXA1)
| Code | Size | Price |
|---|
| MAE787Hu22-20ul | 20ul | £90.00 |
Quantity:
| MAE787Hu22-100ul | 100ul | £169.00 |
Quantity:
| MAE787Hu22-200ul | 200ul | £229.00 |
Quantity:
| MAE787Hu22-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunofluorescence (IF)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ANX-A1; ANX1; LPC1; Lipocortin I; Chromobindin-9; Calpactin II; Phospholipase A2 inhibitory protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Annexin A1
Potency (Clone Number):
2#
Reactivity:
Mu;Ra;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL<br/>Immunohistochemistry: 5-20ug/mL<br/>Immunocytochemistry: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
References
http://www.zgxdyx.com/CN/article/downloadArticleFile.do?attachType=PDF&id=8686;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Annexin A1 (ANXA1) | RPE787Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||